WO2006062072A1 - 転移癌治療剤および癌転移抑制剤 - Google Patents
転移癌治療剤および癌転移抑制剤 Download PDFInfo
- Publication number
- WO2006062072A1 WO2006062072A1 PCT/JP2005/022327 JP2005022327W WO2006062072A1 WO 2006062072 A1 WO2006062072 A1 WO 2006062072A1 JP 2005022327 W JP2005022327 W JP 2005022327W WO 2006062072 A1 WO2006062072 A1 WO 2006062072A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- metastasis
- cancer metastasis
- liver
- bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a metastatic cancer therapeutic agent and a cancer metastasis inhibitor, and more particularly to a metastatic cancer therapeutic agent and a cancer metastasis inhibitor which are particularly effective for cancer metastasis to bone and / or liver.
- Non-Patent Document 2 reports a metastasis-suppressing effect by prophylactic administration of bone metastases such as breast cancer and prostate cancer by a bisphosphonate preparation.
- Non-Patent Document 3 reports that bisphosphonate preparations do not contribute to prolonging the life of patients and that the growth inhibitory action on cancer cells present in bone is weak or does not show growth inhibitory action. Yes.
- Non-Patent Document 1 TGAllen-Mersn et a. Quality of Life and Survival with continuous Hepatic-Artery Floxuridine Infusion for Colorectal Liver Metastases.: "Lancet”: 1994 , 344: ⁇ .1255-1260
- Non-Patent Literature 2 G.N. Hortobagyi et al: Efficacy of Pamidronate in Reducing Skeletal Comomplications in Patients with Breast Cancer and Lytic Bone Metastasis. ⁇ New Englad Journal of Medicine J: 1996,335: p.1785-1791
- Non-Patent Document 3 PFConte et al.: Delay in Progression of Bone Metastases in Breast Cancer Patients Treated with Intravenous Pamidronate: Results from a Multinational Randomized Controlled "1 rial. -2559 "Disclosure of the Invention
- an object of the present invention is to treat metastasized cancer and suppress cancer metastasis, in particular, to effectively treat and suppress metastasized cancer to bone and liver, and has excellent safety for metastatic cancer and cancer. It is to provide a metastasis inhibitor.
- platinum preparations known as anticancer agents that inhibit the growth of cancer cells by binding to DNA have a therapeutic effect on metastatic cancer.
- the metastatic cancer therapeutic agent and cancer metastasis inhibitor of the present invention are characterized in that a platinum complex having an anticancer activity is an active ingredient.
- Cisbratin can be preferably used as the platinum complex, and the primary cancer in the metastatic cancer therapeutic agent and the cancer to be metastasized in the cancer metastasis inhibitor include colon cancer, prostate cancer, gynecological cancer. Stomach cancer, multiple myeloma, liver cancer, lung cancer, knee cancer, thyroid cancer, kidney cancer, bile duct cancer, gallbladder cancer, neuroblastoma and Hodgkin lymphoma.
- gynecological cancer means breast cancer, endometrial cancer, ovarian cancer, cervical cancer.
- the therapeutic agent for metastatic cancer of the present invention can be suitably used for bone and / or liver metastatic cancer.
- the cancer metastasis inhibitor of the present invention can be suitably used as a cancer metastasis inhibitor that suppresses metastasis to bone and / or liver.
- those containing bisphosphonate as an active ingredient can also be suitably used, and in particular, metastasis to bone can be treated and suppressed. It can also be used as an orally administered drug.
- the metastatic cancer therapeutic agent and cancer metastasis inhibitor of the present invention containing a platinum complex as an active ingredient can treat and / or suppress cancer metastasis, particularly cancer metastasis to bone and liver.
- cancer metastasis particularly cancer metastasis to bone and liver.
- bisphosphonates more effectively treat metastases and
- platinum preparations suppress not only metastasis but also cancer growth, they can be drugs that can simultaneously have the effect of treating, suppressing and preventing metastasis. Furthermore, it can be used as an orally administered agent, and can be provided as a cancer metastasis therapeutic agent and inhibitor excellent in safety.
- the present invention is a metastatic cancer therapeutic agent and a cancer metastasis inhibitor, wherein a platinum complex is an active ingredient.
- Platinum complexes are also known as anticancer agents that inhibit the growth of cancer cells by binding to DNA.
- cisplatin, carboplatin, nedaplatin, and oxalibratin are known as platinum complexes used in the present invention, and cisplatin can be preferably used.
- the primary cancer in the therapeutic agent for metastatic cancer of the present invention, and the cancer to be metastasized in the cancer metastasis inhibitor include colon cancer, prostate cancer, gynecological cancer, gastric cancer, multiple myeloma, liver. Cancer, lung cancer, knee cancer, thyroid cancer, kidney cancer, bile duct cancer, gallbladder cancer, neuroblastoma and Hodgkin lymphoma, etc., especially gynecological cancers such as breast cancer, prostate cancer, lung cancer Colorectal cancer is a cancerous cancer that has metastasized to the bone and liver, etc., and both are useful because they are difficult to cure.
- the metastatic cancer therapeutic agent and cancer metastasis inhibitor of the present invention are pharmacologically acceptable production aids.
- an active ingredient can be administered orally or parenterally as a pharmaceutical composition.
- the dosage form is not particularly limited, but in the case of oral administration, it can be made into solid preparations such as tablets, powders and capsules or liquid preparations such as syrups according to conventional methods.
- parenteral agents it can be used in dosage forms that are usually used, such as injections and inhalants.
- the pharmaceutical composition of the present invention can be prepared by mixing pharmacologically and pharmaceutically acceptable additives as necessary.
- additives include known additives such as excipients, binders, diluents, disintegrants, stabilizers, and lubricants. Appropriate sterilization treatment is required for injections.
- a capsule agent containing a composition containing a platinum complex and polyethylene glycol as essential components is used.
- the platinum complex itself has carcinogenicity and has strong side effects.
- the water content of the composition that is the content of the capsule is 10% W / W or less with respect to the essential components (see JP-A-10-279478).
- the dose of the platinum complex according to the present invention varies depending on the patient's carcinoma, symptoms, age, sex, body weight, type of platinum complex, dosage form, and administration form.
- 0.01 mg / kg to 0.5 mg / kg body weight per kg per adult, preferably 0.02 to 0.2 mg, once a day, 3 days a day, 3 weeks a week, 1 week off It is appropriate to administer 6 courses and a maximum of 12 courses.
- the metastatic cancer therapeutic agent and the cancer metastasis inhibitor of the present invention are preferably used in combination with bisphosphonate as an active ingredient.
- the bisphosphonate used in the present invention is a compound having a P_C_P structure as a basic structure and having an action on bones such as an osteoclast bone resorption inhibitory action.
- a compound having a P_C_P structure as a basic structure and having an action on bones such as an osteoclast bone resorption inhibitory action.
- Bisphosphonate The dosage, administration method, administration period, etc. are appropriately selected according to the patient's carcinoma, symptoms, age, sex, body weight, type of bisphosphonate, and the like.
- mice 8-week-old female C57BL / 6 mice (12 mice / group) were transplanted with 10 4 melanoma B16 cells / 0.1 mL in the left ventricle according to the method described above. Starting 1 day later, cisplatin lmg / kg / day was orally administered daily, and mice were weakened or paralyzed 3 weeks later when sacrificed with ether inhalation, the target organ was fixed with 10% formalin, and the tumor was Metastasis assessment was performed. The number of individuals with confirmed metastasis is shown in Table 2 below.
- cisplatin lmg / kg / day and Aredia lmg / kg / day were combined on the same schedule as the single agent (cisbratin + Aredia group).
- the serum human IgE (h IgE) level was measured 29 days after tumor transplantation and the therapeutic effect on bone metastasis was examined (Y.Miyakawa et al .: Establis hment of a newmodel of human multiple myeloma using NOD / SCID / yc (NOG) mic e. “Biochemical and Biophysical Research Com solidificationj: 2004, 313: 258-262”.
- the results regarding the amount of human IgE in the obtained serum are shown in Table 3 below.
- Tumor growth delay rate (%) (8—B) / B X 100 (1)
- A is the number of days required to increase the tumor volume of each group administered cisbratin by 8 times
- B is the number of days required to increase the tumor volume of the control group by 8 times.
- blood urea nitrogen (BUN) was measured as an index of nephrotoxicity. The results obtained are shown in Table 4 below.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05814661A EP1832293A4 (en) | 2004-12-10 | 2005-12-06 | MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT |
US11/792,519 US20080069901A1 (en) | 2004-12-10 | 2005-12-06 | Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor |
JP2006546689A JPWO2006062072A1 (ja) | 2004-12-10 | 2005-12-06 | 転移癌治療剤および癌転移抑制剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004358471 | 2004-12-10 | ||
JP2004-358471 | 2004-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006062072A1 true WO2006062072A1 (ja) | 2006-06-15 |
Family
ID=36577899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022327 WO2006062072A1 (ja) | 2004-12-10 | 2005-12-06 | 転移癌治療剤および癌転移抑制剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080069901A1 (ja) |
EP (1) | EP1832293A4 (ja) |
JP (1) | JPWO2006062072A1 (ja) |
KR (1) | KR20070092972A (ja) |
WO (1) | WO2006062072A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2937867B1 (fr) * | 2008-11-03 | 2011-03-04 | Biorebus | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. |
CN104586887A (zh) * | 2015-02-09 | 2015-05-06 | 江苏澳格姆生物科技有限公司 | 顺铂在制备抑制肿瘤细胞转移和扩散的药物中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS625911A (ja) * | 1985-04-30 | 1987-01-12 | スロ−ン−ケツタリング インステイテユ−トフオ− キヤンサ− リサ−チ | 骨の疾患を治療する方法 |
JPH02502182A (ja) * | 1987-02-19 | 1990-07-19 | アスタ・メディカ・アクチエンゲゼルシャフト | プラチナ錯体、その製法およびそれを含有する薬剤 |
JPH03504715A (ja) * | 1988-02-15 | 1991-10-17 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチェン | 細胞増殖抑制剤またはホルモン治療剤およびホスホノ誘導体の組み合わせを含有する薬剤 |
JPH11322616A (ja) * | 1998-05-08 | 1999-11-24 | 一周 ▲バエ▼ | 天然化学物質六酸化四砒素の新規の抗腫瘍治療剤としての用途及びその薬学的組成物 |
WO2001097849A1 (fr) * | 2000-06-23 | 2001-12-27 | Mitsubishi Pharma Corporation | Potentialisateurs d'effet antitumoral |
JP2003515534A (ja) * | 1999-11-16 | 2003-05-07 | オンコザイム ファーマ、インコーポレーテッド | がん治療のためのエンド−エクソヌクレアーゼ活性の阻害剤 |
WO2005000858A2 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1248654B (de) * | 1964-11-11 | 1967-08-31 | Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) | Verfahren zur Herstellung von Phosphonsäuren und deren Salzen |
DE2943498C2 (de) * | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
IT1196315B (it) * | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
IL84497A (en) * | 1986-11-21 | 1994-10-21 | Ciba Geigy Ag | History 2-) Imidazol-1-yl (ethane-1,1-diphosphonic acid, their preparation and pharmaceutical preparations containing them |
FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
US7598246B2 (en) * | 1998-04-02 | 2009-10-06 | Mbc Pharma, Inc. | Bisphosphonate conjugates and methods of making and using the same |
US6750340B2 (en) * | 1998-04-02 | 2004-06-15 | Mbc Research, Inc. | Bisphosphonate conjugates and methods of making and using the same |
-
2005
- 2005-12-06 US US11/792,519 patent/US20080069901A1/en not_active Abandoned
- 2005-12-06 EP EP05814661A patent/EP1832293A4/en not_active Withdrawn
- 2005-12-06 WO PCT/JP2005/022327 patent/WO2006062072A1/ja active Application Filing
- 2005-12-06 JP JP2006546689A patent/JPWO2006062072A1/ja not_active Withdrawn
- 2005-12-06 KR KR1020077014788A patent/KR20070092972A/ko not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS625911A (ja) * | 1985-04-30 | 1987-01-12 | スロ−ン−ケツタリング インステイテユ−トフオ− キヤンサ− リサ−チ | 骨の疾患を治療する方法 |
JPH02502182A (ja) * | 1987-02-19 | 1990-07-19 | アスタ・メディカ・アクチエンゲゼルシャフト | プラチナ錯体、その製法およびそれを含有する薬剤 |
JPH03504715A (ja) * | 1988-02-15 | 1991-10-17 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチェン | 細胞増殖抑制剤またはホルモン治療剤およびホスホノ誘導体の組み合わせを含有する薬剤 |
JPH11322616A (ja) * | 1998-05-08 | 1999-11-24 | 一周 ▲バエ▼ | 天然化学物質六酸化四砒素の新規の抗腫瘍治療剤としての用途及びその薬学的組成物 |
JP2003515534A (ja) * | 1999-11-16 | 2003-05-07 | オンコザイム ファーマ、インコーポレーテッド | がん治療のためのエンド−エクソヌクレアーゼ活性の阻害剤 |
WO2001097849A1 (fr) * | 2000-06-23 | 2001-12-27 | Mitsubishi Pharma Corporation | Potentialisateurs d'effet antitumoral |
WO2005000858A2 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
Non-Patent Citations (4)
Title |
---|
F. ARGUELLO ET AL.: "A Murine Model of Experimental Metastasis to Bone and Bone Marrow", CANCER RESEARCH, vol. 48, 1988, pages 6876 - 6881 |
GROHN P ET AL: "Successful management of a widespread osteosarcoma. A case report.", MEDICAL PRINCIPLES AND PRACTICE: INTERNATIONAL JOURNAL OF THE KUWAIT UNIVERSITY., vol. 13, no. 1, January 2004 (2004-01-01) - February 2004 (2004-02-01), pages 54 - 56, XP002995575 * |
KLENNER T ET AL: "Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?", J CANCER RES CLIN ONCOL., vol. 116, no. 4, 1990, pages 341 - 350, XP002995574 * |
See also references of EP1832293A4 |
Also Published As
Publication number | Publication date |
---|---|
US20080069901A1 (en) | 2008-03-20 |
EP1832293A1 (en) | 2007-09-12 |
KR20070092972A (ko) | 2007-09-14 |
EP1832293A4 (en) | 2009-01-07 |
JPWO2006062072A1 (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105849110B (zh) | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 | |
JP2014132009A5 (ja) | ||
CN104043125A (zh) | 诱导肿瘤缺氧以治疗癌症 | |
JP6656397B2 (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
US10828271B2 (en) | Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation | |
CA2596084A1 (en) | Treatment of metastasized tumors with quinolinone benzimidazole compounds | |
MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
JP2021169534A (ja) | 化学療法の改善 | |
JP2008528617A5 (ja) | ||
JPH11322596A (ja) | 白金錯体および環状リン酸エステルアミドを含有する抗癌剤 | |
Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
JP2001139476A (ja) | 癌を含めた悪性新生物に用いる抗悪性腫瘍剤 | |
WO2006062072A1 (ja) | 転移癌治療剤および癌転移抑制剤 | |
KR101135789B1 (ko) | 피리딘 유도체를 유효성분으로 하는 방사선 치료 증강제 | |
KR101245328B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물을 포함하는 항암제 조성물 | |
ES2745506T3 (es) | Combinación antitumoral que comprende cabazitaxel y cisplatino | |
JP2016503035A (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
JP2006523664A5 (ja) | ||
WO1992011247A1 (en) | Anticancer composition and compound | |
CN1151793C (zh) | 多发性骨髓瘤的骨病变治疗用医药组合物 | |
EP0794786A1 (en) | The use of inositoltrisphosphate for the preparing of medicaments | |
WO2016014390A1 (en) | Compositions and methods for mek inhibitor combination therapy in the treatment of cancer | |
Hori | Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700) | |
JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
RU2341260C2 (ru) | Комбинации, включающие производные эпотилона и алкилирующие агенты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006546689 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077014788 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005814661 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005814661 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11792519 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11792519 Country of ref document: US |